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A B S T R A C T
CD25 deficiency is a very rare autosomal recessive disorder that shows a clinical phenotype highly overlapping
IPEX syndrome with an increased susceptibility to viral, bacterial, and fungal infections. It is due to mutations in
the IL2Rα gene that codes for the α subunit of the IL2 receptor complex.
Here we report the characterization of a novel IL2Rα gene mutation leading to a severe protein conforma-
tional alteration that abrogates its cell surface expression in a child presenting with early-onset IPEX-like dis-
order. Cytofluorimetric analysis revealed the total absence of CD25 cell surface expression and addressed IL2Rα
molecular investigation.
The early clinical and molecular diagnosis of CD25 deficiency in this patient promptly led to hematopoietic
stem cell transplantation (HSCT), allowing complete resolution of the symptoms and definitive cure of the
disease.
1. Introduction
CD25 deficiency (OMIM #606367) is a rare genetic disorder that
shows an autosomal recessive inheritance. It was first described by
Sharfe et al. in 1997 as an immunodeficiency characterized by in-
creased susceptibility to viral, bacterial and fungal infections and de-
creased numbers of peripheral T cells with abnormal proliferation [1].
In 2007, Caudy et al. associated the deficiency of CD25 with IPEX-like
phenotype since the reported patient showed clinical features resem-
bling Immunedysregulation Polyendocrinopathy Enteropathy X-linked
(IPEX) Syndrome caused by FOXP3 mutations, with a greater suscept-
ibility to infections [2].
To date, only eight cases of six unrelated families have been re-
ported (Supplementary information is available on EJHG's website,
Table 2) [1–6]. All patients showed an early onset of symptoms and
four of them presented with severe autoimmune enteropathy with
histological findings of villous atrophy and several infections (usually
viral and/or opportunistic) as common features. Four patients, in-
cluding three patients of the same family, presented with auto-
immunity, such as autoimmune cytopenias and diabetes as main clin-
ical features. Five out of eight patients also developed severe eczema,
while the presence of other autoimmune phenomena was more het-
erogeneous.
CD25 deficiency is due to mutations in the IL2Rα gene (OMIM
147730; chr10p15.1) coding for the α subunit (CD25) of the IL2 re-
ceptor complex that, together with β (CD122) and γ (CD132) subunits,
composes the high-affinity receptor for IL2. It has been suggested that
IL-2Rα captures and concentrates free IL-2 at the cell surface for pre-
sentation to IL-2Rβ and γc or that IL2/IL-2Rα interaction induces
conformational changes in IL-2 that stabilizes the formation of the
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ternary complex IL-2Rαβγ [7]. CD25 is highly expressed on the surface
of regulatory T cells (Tregs) that actively suppress pathological and
physiological immune responses, thereby contributing to the main-
tenance of immunological self-tolerance and immune homeostasis [8].
The presence of CD25 enables Tregs to be the first responders to IL2
during an immune response [9] and allows the transcription of FOXP3
through the IL2/IL2Rα-STAT5b transduction pathway [10].
Here we report the characterization of a novel IL2Rα gene mutation
leading to a conformational alteration of protein subunits and con-
sequential absence of cell surface expression in a patient presenting
with early onset autoimmunity.
2. Subjects and methods
2.1. Case report
The patient was a two-month-old boy born to unrelated parents with
uneventful pregnancy and delivery. At one month of age, he developed
intractable watery diarrhoea that required parenteral nutrition (PN).
Small bowel biopsies showed villous atrophy upon histopathological
examination. Pseudomonas and Human herpesvirus 6 (HHV6) in stool
were detected. He also developed severe dermatitis. Laboratory eva-
luation showed normal complete blood count, normal immunoglobulin
serum levels (IgG 789mg/dl; IgA 150mg/dl; IgM 260mg/dl) and
mildly elevated IgE (169 kU/l). Immunophenotyping revealed a de-
crease of total lymphocytes in particular of naïve T cells, both CD4
(patient 44.5%, healthy controls, HC 66–100%) and CD8 (patient
55.7%, HC 78.5–97.1%), and a decrease of recent thymic emigrants
(patient 23.6%, HC 50–100%). Total B cells were lower compared to HC
(patient 5%, HC 20.5–40.9%) (Supplementary information is available
on EJHG's website, Table 1).
2.2. Flow cytometry
Peripheral Blood Mononuclear Cells (PBMCs) of patient and HC
were obtained by Ficoll-Paque PREMIUM (GE Healthcare, UK). Surface
antibodies staining was performed for 15min in the absence of light
using a 0.5% bovine serum albumin PBS mixture. Cells were washed
and treated with FOXP3 perm/fix buffer set (BioLegend, CA, USA) to be
further stained for FOXP3. The following antibodies were used: CD4-
PerCp-Cy5.5 (SK3), CD25-PE (M-A251), CD127-AlexaFluor647 (HIL-
7R-M21), FOXP3-AlexaFluor488 (259D, BioLegend).
To evaluate CD25 intracytoplasmic expression, lymphocytes were
stimulated with Dynabeads® CD3/CD28 T Cell Expander beads
(Invitrogen, Thermo Fisher Scientific) and recombinant human IL-2
(rhIL-2, 100 U/ml) (PeproTech®, USA) and stained with antibodies to
CD25-PE (2AE), CD4-APC (SK3), CD3-PE-Cy7 (SK7) and LIVE/DEAD®
Fixable viability dye (Invitrogen, Thermo Fisher Scientific, Italy). Cells
were fixed and permeabilized with FOXP3 perm/fix buffer and stained
for intracytoplasmic CD25-FITC (M-A251).
All antibodies were purchased from BD Biosciences unless otherwise
noted. Cells were acquired with FASCanto II and the analysis was
performed with FACSDiva Software (BD Biosciences, USA).
2.3. Proliferation assay and cytokine production
Proliferation and cytokine production were investigated both in
deficient patient and in HC, as described [11]. Polyclonal stimulation of
PBMCs from HC and the patient was performed by culturing at 5×104
cells per well in duplicate in round-bottom 96-well tissue culture plates
with medium, in presence of CD3/CD28 T Cell Expander alone or plus
rhIL-2 in different concentrations (10 U/ml, or 100 U/ml, or 1000 U/
ml), or rhIL-15 (10 ng/ml) (R&D system, UK). Furthermore 5×104
cells per well in duplicate were stimulated with the same stimulation
media or with rhIL-2 (100 U/ml) plus rhIL-15 (10 ng/ml) medium
without CD3/CD28 T Cell Expander. As negative control, cells were
plated at 5× 104 cells per well in duplicate with medium without sti-
muli. The cells were cultured for 3 days before pulsing with [3H]thy-
midine for 18 h. Plates were harvested and proliferation was recorded
as counts per minute (CPM) using a beta counter.
To assess cytokine production, 5×105 cells of the patient or the HC
were stimulated with 0.5 ml medium in presence or absence of PMA
10 ng/ml and ionomycin 1 μg/ml (Sigma-Aldrich) for 36 h. At the end
of the culture period, cell-free supernatants were collected and assayed
for their cytokine content (IFN-γ, IL-4, IL-17) by ELISA (Invitrogen,
Thermo Fisher Scientific, Italy).
2.4. Molecular analysis
Genomic DNA was isolated from peripheral blood leukocytes using
the QIAamp DNA Blood Mini Kit according to the manufacturer's in-
structions (Qiagen, Hilden, Germany).
The entire coding sequence, including exon–intron junctions, was
amplified using exon-specific primers (sequences available upon re-
quest) and standard PCR conditions. PCR products were sequenced
using the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems,
Foster City, CA, USA) on an automated ABI PRISM 3130 Genetic
Analyzer (Applied Biosystems) and compared to reported reference
cDNA sequence (GenBank accession no. NM_000417.2). Written in-
formed consent to genetic investigations, approved by the local ethics
committee, was obtained from the patient's family.
2.5. Bioinformatic analysis
The presence of the patient's sequence variant in the general po-
pulation and its frequency was assessed using the following databases:
dbSNP (Single Nucleotide Polymorphisms database) by the National
Center for Biotechnology Information (NCBI) (www.ncbi.nlm.nih.
gov/projects/SNP/) [12];
Exome Variant Server (NHLBI GO Exome Sequencing Project (ESP),
Seattle, WA (http://evs.gs.washington.edu/EVS/);
Exome Aggregation Consortium (ExAC), Cambridge, MA (URL:
http://exac.broadinstitute.org), Version 0.3 January 13, 2015.
Prediction analysis of sequence variant effects on the protein
structure/function was performed using the following software: Alamut
Visual version 2.4 (Alamut Visual version 2.6 (Interactive Biosoftware,
Rouen, France, http://www.interactive-biosoftware.com/alamut-
visual, including SIFT [sort intolerant from tolerant human protein],
Mutation Taster, and Polyphen-2 [Polymorphism Phenotyping v2]).
2.6. Structural analysis
The putative structure of the CD25 altered form, the object of this
study, has been predicted by Homology Modeling (HM) using SWISS-
MODEL (http://swissmodel.expasy.org). The p.Cys51Gly IL2Rα amino
acid sequence was used as target for the HM analysis and the structure
of wild type IL2Rα (sushi D1 and D2 domains) as template. The PDB
files generated by HM were superimposed with the structure of wild
type sushi domains of the human IL2Rα structure by PyMOL software
(The PyMOL Molecular Graphics System, Version 0.99, DeLano
Scientific, LLC, San Carlos, CA).
3. Results
3.1. Lack of surface CD25 protein expression
The cytofluorimetric analysis of freshly isolated PBMCs from the
patient revealed total absence of cell surface CD25 expression on CD4+
T cells (Fig. 1A), while CD25 was detected on CD4+ T cells of parents
and HC. CD25 surface expression on CD4+ T cells of the patient re-
mained undetectable upon TCR-mediated activation even in the pre-
sence of exogenous IL-2, while CD4+ T cells of a HC tested in parallel
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showed an increase of surface CD25 expression (Fig. 1B). The percen-
tage of FOXP3-expressing CD4+ T cells was comparable to HC (Fig. 1C).
Further cytofluorimetric analysis in freshly isolated PBMCs from the
patient and HC revealed the presence of intracytoplasmic CD25 ex-
pression. In particular CD4+ T cells showed a boost in intracytoplasmic
CD25 expression immediately after T cells activation and in the pre-
sence of exogenous IL2, although the patient showed lower levels of
CD25 expression compared to HC (Fig. 1D).
3.2. Novel missense mutation in IL2Rα gene
Molecular analysis of the IL2Ra gene sequence on the patient's
gDNA revealed the presence of a previously unreported mutation. The
patient resulted homozygous for a c.151 T > G transversion located in
exon 2, leading to the substitution of the amino acid Cysteine at codon
51 with a Glycine (p.Cys51Gly) within the Sushi Domain D1 of the
protein. The patient's parents proved to be heterozygous for the same
mutation. The variation was absent in the 6500 exomes analysed by the
Exome Sequencing Project (ESP) and in the 60,700 exomes evaluated
by the Exome Aggregation Consortium (ExAC).
The reported crystal structure of the wild-type IL2Rα indicates that
the cysteine residue at codon 51 is involved in intradomain D1 dis-
ulfide-bond formation. Sequence alignment data showed that the re-
sidue is highly conserved among species and bioinformatic analysis of
the variation indicated that the amino acid change might be deleterious
for protein structure.
3.3. Mutated protein structure instability
To get better insight into the molecular level of possible effects of
the p.Cys51Gly on the protein structure, the putative structure of the
altered subunit of CD25 was obtained by HM. In the mutated protein
form the disulfide bond Cys51-Cys82, that stabilizes the sushi domain 1,
is lost. Four different models of CD25 p.Cys51Gly were obtained by HM
analysis. These multiple models computed by HM suggest increased
entropy and instability of the protein structure once the disulfide bond
is lost (Fig. 1E).
3.4. Defective proliferative response and cytokine production
We performed a proliferative assay to evaluate the ability of pa-
tient's T cells to respond to polyclonal TCR-mediated stimulation using
anti-CD3/CD28 monoclonal antibodies (mAb) and the ability to re-
spond to IL-2 through rhIL-2 stimulation. We also tested the pro-
liferative response to rhIL-15 to asses if the eventual absence to IL-2
response could be partially replaced by the IL-2Rβ signalling. The pa-
tient's T cells showed a poor response to non-specific TCR activation
compared to HC and showed also a mild, dose-dependent proliferation
to rhIL-2, although the response was not as vigorous as in HC.
Additionally, the patient's T cells response to rhIL-15 was present but
poor (Fig. 2A).
Cytokine production showed that patient's cells, when stimulated,
were able to produce only IFN-γ (626 ± 52 pg/ml) compared to not
stimulated cells. No significant production of IL-17 or IL-4 was found.
Fig. 1. CD25 expression and protein structure. (A) Surface CD25 expression on resting CD4+ T cells in the patient and HC. (B) Surface CD25 expression on CD4+ T
cells stimulated with CD3/CD28 T cell expander beads+ rhIL2 (100 U/ul) in patient and HC. (C) Intracytoplasmic FOXP3 expression in CD4+ T cells in the patient
and HC. (D) Intracytoplasmic CD25 expression in CD4+ T cells stimulated with CD3/CD28 T cell expander beads+ rhIL2 (100 U/ml) in patient and HC. Values are
expressed as percentage of CD4+T cells. (E) Representative model of altered CD25 putative structure form predicted by Homology Modeling. Wild-type CD25
structure in blue with disulfide bond Cys51-Cys82 in red. Model of p.Cys51Gly CD25 structure in light blue. Superposition of wild-type and model of p.Cys51Gly
CD25 structure is shown. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Conversely, HC stimulated cells were able to produce all three tested
cytokines compared to not stimulated cells and cytokine levels resulted
significantly higher than those detected in the patient's cells (IFN-γ:
8298 ± 175 pg/ml, IL-4: 140 ± 26 pg/ml, IL-17: 315 ± 33 pg/ml)
(Fig. 2B).
4. Discussion
This paper reports the case of a two-month-old boy presenting with
early onset enteropathy and dermatitis resembling IPEX syndrome.
Cytofluorimetric analysis revealed the total absence of CD25 cell sur-
face expression. This result quickly addressed the molecular investiga-
tion towards the analysis of IL2Rα gene sequence, which showed the
presence of a novel homozygous missense variation (c.151 T > G;
p.Cys51Gly). The sequence variant is predicted to cause the replace-
ment of a Cysteine that is involved in an intra-domain D1 disulfide-
bond formation. Previous studies of IL2Rα crystal structure revealed
that the two “sushi–like” domains D1 and D2 are in intimate contact
with one another through an extensive inter-domain interface and that
intra- and inter-domain disulfide bonds enforce the stability of the
structure and the strand exchange [13,14].
To further investigate the effect of IL2Rα mutation on protein
structure, we analysed the putative configuration of the altered subunit
by HM analysis. Four different models were obtained and compared to
the wild type protein structure; for all of them the lack of the disulfide
bond found in the patient led to a total loss of the correct folding of the
protein in sushi 1 domain.
We hypothesise that the disruption of D1 disulfide-bond between
Cysteins 51 and 82 due to amino acid change could lead to alteration of
the protein structure and to subsequent degradation of the misfolded
subunit after its synthesis.
Cells possess a highly active quality control system that recognizes
the folding state of proteins, detects terminally misfolded proteins, and
specifically eliminates them by proteolysis. The endoplasmic reticulum
associated degradation (ERAD) machinery retro-translocate misfolded
proteins back to cytosol where the ubiquitin proteasome system (UPS),
the major cellular protein elimination machinery in eukaryotic cells, is
located [15].
Cytofluorimetric analysis strongly supported our hypothesis re-
vealing the presence of intracytoplasmic CD25 expression in patient's
CD4+ T cells, thus confirming that the variation does not abrogate
IL2Rα transcription and translation, but shows the absence of cell sur-
face CD25 expression as a result of possible misfolded protein de-
gradation.
The proliferative assay on the patient's PBMCs confirmed an im-
pairment to non-specific TCR activation, as well as to IL2 and IL15 dose-
dependent proliferation. This is due to the binding of IL2 to IL2βγ low
affinity complex and of IL15 to the complex IL15Rα-IL2Rβ that helps to
by-pass the lack of IL2. Cytokine studies also confirmed an altered ac-
tivation profile in the patient compared to HC.
IPEX syndrome, due to FOXP3 mutation, was one of the first dis-
eases of monogenic autoimmunity to be described. Various forms of
congenital immunedysregulation, not showing FOXP3 mutations, have
been labelled over time and somehow improperly as “IPEX-like” dis-
eases. CD25 deficiency syndrome is a rare autosomal recessive disorder
of overwhelming autoimmunity and may be considered the only real
phenocopy of IPEX. Prompt treatment with HSCT is the only possible
cure of for the disease. Therefore, a timely clinical and molecular di-
agnosis of CD25 deficiency is mandatory for a successful therapeutic
intervention. The patient described in this paper underwent, at three
months of age, haploidentical allogeneic HSCT using TCR a/b and CD19
depletion and reduced intensity conditioning (RIC) with treosulfan,
fludarabine and antithymocyte globulin (ATG) and anti-CD20 as graft-
versus-host disease (GvHD) prophylaxis, however no engraftment was
attained. A second successful HSCT from matched unrelated donor was
performed at seven months of age using a RIC regimen with low-dose
busulfan and fludarabine and ATG, metrotexate and ciclosporin as
GvHD prophylaxis. The patient showed a reasonable immune recon-
stitution, a good donor chimerism (95% donor 5% recipient) at four
months post HSCT, and a complete resolution of the symptoms. He
developed a mild skin GvHD which was successfully treated with im-
mune suppression.
This report underlines the importance of cytofluorimetric analysis
as a diagnostic tool of CD25 deficiency. As pointed out by our results
and in agreement with previous reports in literature, all patients
identified to date with IL2Rα gene mutations have shown total absence
or markedly reduced CD25 cell surface expression. As reported by
Goudy et al, CD25 protein expression is maintained in the cytoplasm,
although at a lower level compared to healthy controls [3]. Im-
munophenotyping of Tregs can be considered an effective screening
tool to discriminate between IPEX and CD25 deficiency syndrome and
can neatly address molecular diagnosis. Furthermore, HM is a valuable
Fig. 2. Proliferation assays and cytokine profile of CD25 deficient and healthy T cells. (A) Proliferative response to polyclonal stimulation in CD25 deficient patient
and HC. PBMCs from the patient and HC were stimulated with CD3/CD28 T cell expander (Anti-CD3/CD28 mAb) in the presence or absence of different con-
centrations of rhIL-2 or rhIL-15, and proliferation was determined by 3H-thymidine after 3 days (B) Cytokine production profile of PBMCs from the patient and HC in
presence of PMA and ionomycin.
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method to predict protein structure in IL2Rα mutated subunits and
possible effects of gene variants on the protein stability.
In conclusion, a well-defined clinical and immunophenotypic
characterization of CD25 deficiency syndrome will allow an early mo-
lecular diagnosis and promptly lead to the appropriate treatment of the
disease.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.clim.2019.02.003.
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